GC
PRAX icon

Guggenheim Capital’s Praxis Precision Medicines PRAX Stock Holding History

Guggenheim Capital’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Buy
3,846
+1,176
+44% +$372K 0.01% 909
2026
Q1 		$860K Buy
+2,670
New +$826K 0.01% 1034

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Guggenheim Capital's PRAX Position: Q2 2026 in Review

Guggenheim Capital increased its Praxis Precision Medicines (PRAX) stake by 44% in Q2 2026, buying an estimated $372K and bringing the position to 3,846 shares worth $1.29M. The position accounts for 0.01% of the portfolio, ranked #909.

Guggenheim Capital first reported a position in PRAX in Q1 2026 and has held it in 2 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Guggenheim Capital held 3,846 shares of Praxis Precision Medicines worth $1.29M as of Q2 2026.
  • Guggenheim Capital bought 1,176 Praxis Precision Medicines shares in Q2 2026, an estimated $372K.
  • Praxis Precision Medicines made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #909 holding.
  • Guggenheim Capital first reported a position in Praxis Precision Medicines in Q1 2026 and has held it in 2 quarters since.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.